European Barberry (Berberis vulgaris) has been used in traditional medicine for liver ailments, including hepatitis, but there is also a growing body of scientific research investigating its efficacy. The main active compound, berberine, has demonstrated hepatoprotective, anti-inflammatory, and antiviral activities in various preclinical studies. Animal studies have shown that berberine can reduce liver inflammation and oxidative stress, and may help protect against liver damage induced by toxins or viruses. Furthermore, in vitro research indicates that berberine can inhibit the replication of hepatitis B and C viruses, suggesting a potential antiviral effect relevant to hepatitis treatment.

However, robust clinical trials in humans are scarce. Some small-scale trials and case reports suggest that berberine or barberry extracts may improve liver enzyme profiles and alleviate symptoms in patients with chronic hepatitis, but these findings are preliminary. Comprehensive, high-quality clinical studies are needed to confirm efficacy and safety for hepatitis patients. Thus, while scientific evidence exists at the laboratory and animal level, and there is a plausible pharmacological basis, the clinical evidence remains limited, resulting in a moderate (2/5) evidence rating for its use in hepatitis.

In summary, the use of European Barberry for hepatitis is supported by both traditional use and emerging scientific evidence, but not yet by strong clinical data.